Found "Health Policies": 1,019 results
Economic Evaluation of 3-Drug Antiretroviral Regimens for the Prevention of Mother-to-Child HIV Transmission in Thailand (2015)
Pitsaphun Werayingyong, BPharm, MSc1, Nittaya Phanuphak, MD2, Kulkunya Chokephaibulkit, MD3, Sripen Tantivess, BPharm, PhD1, Nareeluk Kullert, BSc4, Kakanang Tosanguan, BPharm1, Rukmanee Butchon, MSc1, Nipunporn Voramongkol, MD4, Sarawut Boonsuk, MD5, Songyot Pilasant, BSc1, Wantanee Kulpeng, BSc1,
A store-and-forward telemedicine for retinopathy of prematurity screen: is it cost-effective in Thailand? (2015)
Phanthipha Wongwai a, Pritaporn Kingkaew b, Somkiat Asawaphureekorn a, Tharatip Kolatat c
aDepartment of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40000, Thailand
bHealth Intervention and Technology Assessment Program (HITAP), Nonthaburi 11000, Thailand
cDepartment of Pa
Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. 2015
Thanthima Suwanthawornkul1, Thunyarat Anothaisintawee2*,
Abhasnee Sobhonslidsuk3, Ammarin Thakkinstian4, Yot Teerawattananon1
1 Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand,
2 Department of Family Medicine, Faculty of Medicine, Ramathibodi
Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016
Full text: http://link.springer.com/article/10.1007s40273-015-0360-1
A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines (2016)
Kittiphong Thiboonboon1 , Benjarin Santatiwongchai1 ,Varit Chantarastapornchit1 , Waranya Rattanavipapong1 , Yot Teerawattananon1
Abstract
Background
For more than three decades, the number and influence of economic evaluations of healthcare interventions have been increasing and gaining atte
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Abstract
BACKGROUND:
Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis
Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia
Abstract
Objectives
This study aims to assess the value for money and budget impact of offering hemodialysis (HD) as a first-line treatment, or the HD-first policy, and the peritoneal dialysis (PD) first policy compared to a supportive care option in patients with end-stage renal disease (ESRD)
Developing and testing quality indicators for the Thai Quality and Outcomes Framework
Primary care serves as an entry point in the Thai health care system. Whilst effective interventions are provided in the primary care setting, the quality of the services have not been measured or tracked. A number of initiatives were undertaken to improve primary health care quality including the u
To include or not include: renal dialysis policy in the era of universal health coverage
SUMMARY POINTS
• End stage renal disease (ESRD) is a life-threatening condition that results in most patients requiring a lifetime of high cost renal dialysis
• Governments have grappled with the political, economic, and ethical challenges of providing treatment with their available budgets
•
Dispelling the myths of providing dialysis in low- and middle-income countries
Public policy for kidney replacement therapy eludes most low- and middle-income countries owing to the seemingly low number of cases and high cost. Countries such as Thailand have shown that public health authorities can effectively provide treatment and elevate health care for populations by overco
10 / Page